FUNDRAISING FOR A CURE
Donating is simple, fast and totally secure. Your details are safe with us and we will never sell them
Cancer patients are still unable to routinely access a treatment through the NHS more than two years after it received positive guidance from the National Institute for Health and Care Excellence (NICE).
PLANETS Cancer Charity is taking its campaign for NHS access to Selective Internal Radiation Therapy (SIRT) to Parliament, backed by more than 49,000 people who have signed a petition calling for change.
SIRT is a targeted treatment for patients with neuroendocrine tumours (NETs) that have spread to the liver.
In May 2024, NICE published guidance recommending SIRT as an option for these patients, subject to standard arrangements for clinical governance, consent and audit.
However, NHS England does not currently routinely commission SIRT for the treatment of NETs that have spread to the liver.
PLANETS says this has left patients who could potentially benefit from the treatment without a clear route to accessing it routinely through the NHS.
The charity will raise the issue at an event in Parliament today (Monday, 12 October) funded by Boston Scientific, which manufactures TheraSphere, a SIRT treatment. It will be attended by patients, clinicians and MPs.
Dr Scott Arthur MP, who introduced the legislation that became the Rare Cancers Act 2026, has backed calls for action.
“Patients with rare cancers deserve access to the most appropriate treatments for their condition, wherever they live,” he said.
“Where NICE has issued positive guidance for a treatment, it is important that we understand what is preventing eligible patients from accessing it through the NHS.
“I look forward to meeting patients and clinicians in Parliament and hearing directly about their experiences of SIRT and the case for making it routinely available to appropriate patients.”
SIRT works by delivering millions of tiny radioactive microspheres through the blood supply directly to tumours in the liver, allowing radiation to be targeted at the cancer while limiting exposure to surrounding healthy tissue.
PLANETS has campaigned for routine NHS access to SIRT since NICE published its guidance in 2024.
Dr Brian Stedman, consultant interventional radiologist at University Hospital Southampton and co-founder of PLANETS Cancer Charity, said: “SIRT will not be the right treatment for every patient with neuroendocrine cancer that has spread to the liver, but for appropriately selected patients it is an important treatment option.
“More than two years after the NICE guidance was published, clinicians should be able to consider SIRT for suitable NHS patients without access being determined by whether they can fund treatment privately.
“We want to see a clear route to routine NHS access so that decisions about SIRT can be made by specialist multidisciplinary teams with expertise in neuroendocrine cancer, based on what is most appropriate for each individual patient.”
The Parliamentary event will bring together patients, clinicians, parliamentarians and other stakeholders to discuss the current barriers to accessing SIRT and call for routine NHS commissioning of the treatment for eligible NET patients.
READ ABOUT HOW FUNDS ARE USED
Subscribe to our Newsletter
Get informed about the latest news straight to your inbox


